Your browser doesn't support javascript.
loading
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
Tjokrowidjaja, Angelina; Lee, Chee K; Friedlander, Michael; Gebski, Val; Gladieff, Laurence; Ledermann, Jonathan; Penson, Richard; Oza, Amit; Korach, Jacob; Huzarski, Tomasz; Manso, Luis; Pisano, Carmela; Asher, Rebecca; Lord, Sarah J; Kim, Se Ik; Lee, Jung-Yun; Colombo, Nicoletta; Park-Simon, Tjoung-Won; Fujiwara, Keiichi; Sonke, Gabe; Vergote, Ignace; Kim, Jae-Weon; Pujade-Lauraine, Eric.
Afiliação
  • Tjokrowidjaja A; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; Department of Medical Oncology, St George Hospital, Kogarah, NSW 2217, Australia. Electronic address: angelina.tjokrowidjaja@ctc.usyd.edu.au.
  • Lee CK; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; Department of Medical Oncology, St George Hospital, Kogarah, NSW 2217, Australia.
  • Friedlander M; Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
  • Gebski V; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia.
  • Gladieff L; Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, 31059 Toulouse, France.
  • Ledermann J; UCL Cancer Institute, University College London, London WC1E 6DD, UK.
  • Penson R; Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Oza A; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada.
  • Korach J; Gynecologic Oncology Department, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, 52621 Tel Aviv, Israel.
  • Huzarski T; Department of Genetics and Pathology, Pomeranian Medical University, 70-204 Szczecin, Poland.
  • Manso L; Hospital 12 de Octubre, 28041 Madrid, Spain.
  • Pisano C; Department of Urogynecology, National Cancer Institute, Pascale Foundation (Scientific Institute for Research and Healthcare), 80131 Naples, Italy.
  • Asher R; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia.
  • Lord SJ; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; School of Medicine, The University of Notre Dame, Sydney, NSW 2007, Australia.
  • Kim SI; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, South Korea.
  • Lee JY; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
  • Colombo N; Gynecology Program, European Institute of Oncology, IRCCS, 20141 Milan, Italy; School of Medicine and Surgery, University Milan Bicocca, 20126 Milan, Italy.
  • Park-Simon TW; Department of Gynaecology and Obstetrics, Medical University Hannover, 30625 Hannover, Germany.
  • Fujiwara K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama 350-0495, Japan.
  • Sonke G; Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Vergote I; Department of Oncology, KU Leuven - University of Leuven, B-3000 Leuven, Belgium; Division of Gynaecological Oncology, University Hospitals Leuven, B-3000 Leuven, Belgium.
  • Kim JW; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, South Korea.
  • Pujade-Lauraine E; Université Paris Descartes, Paris, France; ARCAGY-GINECO, France.
Eur J Cancer ; 139: 59-67, 2020 11.
Article em En | MEDLINE | ID: mdl-32977221
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Antígeno Ca-125 / Recidiva Local de Neoplasia / Antineoplásicos Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Antígeno Ca-125 / Recidiva Local de Neoplasia / Antineoplásicos Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2020 Tipo de documento: Article